Literature DB >> 15050085

Adherence to treatment of depression in active injection drug users: the minerva study.

Michael D Stein1, Debra S Herman, David A Solomon, Jennifer L Anthony, Bradley J Anderson, Susan E Ramsey, Ivan W Miller.   

Abstract

The impact of depression on drug users is extensive, serving as a trigger for high-risk injection practices and continued drug use. Yet the ability to retain active drug users in mental health treatment has never been tested clinically. We recruited injection drug users (IDU) for a randomized study of combined psychotherapy and pharmacotherapy for the treatment of depression. Among the 53 SCID-diagnosed depressed subjects assigned to the combined treatment group, 43.4% were "fully adherent" to treatment (75% or greater attendance at cognitive-behavioral therapy (CBT) sessions or 75% or greater adherence to the pharmacotherapy regimen). The correlation of CBT attendance and pharmacotherapy use was high (r(s) =.74). Persons with double depression (major depression plus dysthymia) were most likely to be fully adherent (p =.01); frequency of heroin use was inversely associated with adherence. Developing public health treatment interventions to engage out-of-treatment, dually-diagnosed IDUs is possible.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15050085     DOI: 10.1016/S0740-5472(03)00160-0

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  4 in total

1.  Medication Adherence Monitoring Using Smartphone Video Dosing in an Open-label Pilot Study of Monthly Naltrexone Plus Once-daily Bupropion for Methamphetamine Use Disorder: Feasibility and Acceptability.

Authors:  Robrina Walker; Maureen Hillhouse; Brian Perrochet; Steven Sparenborg; Larissa Mooney; Walter Ling
Journal:  J Addict Med       Date:  2019 Sep/Oct       Impact factor: 3.702

2.  Impact of HCV treatment and depressive symptoms on adherence to HAART among HIV-HCV-coinfected patients: results from the ANRS-CO13-HEPAVIH cohort.

Authors:  Perrine Roux; Caroline Lions; Julien Cohen; Maria Winnock; Dominique Salmon-Céron; Firouze Bani-Sadr; Philippe Sogni; Bruno Spire; François Dabis; Maria Patrizia Carrieri
Journal:  Antivir Ther       Date:  2013-10-28

3.  Treatment-resistant depression as risk factor for substance use disorders-a nation-wide register-based cohort study.

Authors:  Philip Brenner; Lena Brandt; Gang Li; Allitia DiBernardo; Robert Bodén; Johan Reutfors
Journal:  Addiction       Date:  2019-04-15       Impact factor: 6.526

4.  A Cognitive Behavioral Therapy-Based Text Messaging Intervention Versus Medical Management for HIV-Infected Substance Users: Study Protocol for a Pilot Randomized Trial.

Authors:  Suzette Glasner-Edwards; Kevin Patrick; Michele L Ybarra; Cathy J Reback; Richard A Rawson; Helene Chokron Garneau; Kathryn Chavez; Alexandra Venegas
Journal:  JMIR Res Protoc       Date:  2016-06-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.